|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | +9,900.00% |
|
-.--% | - |
| 12-29 | Motion for Asset Sale Approved for Seelos Therapeutics, Inc. | CI |
| 21/10/25 | GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). | CI |
Company Valuation: Seelos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Market Cap 1 | 36.11 | 84.41 | 172 | 72.77 | 13.61 |
| Change | - | 133.74% | 103.72% | -57.68% | -81.29% |
| Enterprise Value (EV) 1 | 25.85 | 78.47 | 112.2 | 77.36 | 24.85 |
| Change | - | 203.54% | 42.96% | -31.04% | -67.88% |
| P/E | - | -3.7x | -2.24x | -0.98x | -0.18x |
| PBR | -5,174x | 33.5x | 3x | -6.86x | -0.41x |
| PEG | - | - | -0x | 0.2x | 0x |
| Capitalization / Revenue | 96,298,285x | - | - | - | 6,179,954x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -0.93x | - | - | - | - |
| EV / EBIT | -0.93x | -4.18x | -1.82x | -1.09x | -0.61x |
| EV / FCF | -2.79x | -4.82x | -3.7x | -2.17x | -4.86x |
| FCF Yield | -35.8% | -20.8% | -27% | -46% | -20.6% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | - | -1,638 | -2,790 | -2,655 | -989.5 |
| Distribution rate | - | - | - | - | - |
| Net sales | 0.375 | - | - | - | 2.203 |
| EBITDA 1 | -27.71 | - | - | - | - |
| EBIT 1 | -27.75 | -18.76 | -61.67 | -70.92 | -40.5 |
| Net income 1 | -51.26 | -19.1 | -66.05 | -73.53 | -37.88 |
| Net Debt 1 | -10.26 | -5.938 | -59.78 | 4.589 | 11.23 |
| Reference price 2 | 5,145.605269 | 6,067.206212 | 6,259.206409 | 2,607.362669 | 177.920000 |
| Nbr of stocks (in thousands) | 7.02 | 13.9 | 27.5 | 27.9 | 76.5 |
| Announcement Date | 3/17/20 A | 3/11/21 A | 3/4/22 A | 3/10/23 A | 3/6/24 A |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 136 | |
| 21.25x | 6.51x | 14.24x | 1.5% | 56.54B | |
| 31.6x | 7.8x | 24.02x | 0.05% | 53.6B | |
| -17.91x | 4.18x | -7.32x | -.--% | 22.91B | |
| -38.06x | 12.21x | -36.05x | -.--% | 21.37B | |
| 25.45x | 4.98x | 13.18x | -.--% | 20.27B | |
| 24.28x | 4.73x | 15.36x | -.--% | 17.56B | |
| -737.38x | 35.03x | -3943.97x | -.--% | 14.75B | |
| 40.7x | 16.37x | 42.16x | 0.09% | 13.53B | |
| 16.73x | 4.82x | 11.24x | -.--% | 13.33B | |
| Average | -70.37x | 10.74x | -429.68x | 0.18% | 23.39B | |
| Weighted average by Cap. | -32.01x | 9.11x | -238.39x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SEELQ Stock
- Valuation Seelos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
